Please note when clicking links in our content you will be led outside of the Glaukos Facebook page. The site you opt to connect to does not adhere to our privacy policy. You are solely responsible for your interactions on outside websites.
iStent®: An Advanced Device for Glaucoma Therapy.
See Important Safety Information: http://bit.ly/2csw7W7
If you have been managing your glaucoma with medication, and are now preparing for cataract surgery, iStent may be an ideal option for you. iStent is not only the world's smallest medical device known to be implanted in the human body- it also started a revolution in glaucoma treatment as the first Micro-Invasive Glaucoma Surgery (MIGS) device.
Cataract surgery and glaucoma therapy- all in one procedure.
Implanted in the eye during cataract surgery, iStent is designed to reduce eye pressure, which can help prevent the progression of glaucoma and may allow your doctor to reduce your glaucoma medication.
iStent®: An Advanced Device for Glaucoma Therapy.
See Important Safety Information: http://bit.ly/2csw7W7
If you have been managing your glaucoma with medication, and are now preparing for cataract surgery, iStent may be an ideal option for you. iStent is not only the world's smallest medical device known to be implanted in the human body- it also started a revolution in glaucoma treatment as the first Micro-Invasive Glaucoma Surgery (MIGS) device.
Cataract surgery and glaucoma therapy- all in one procedure.
Implanted in the eye during cataract surgery, iStent is designed to reduce eye pressure, which can help prevent the progression of glaucoma and may allow your doctor to reduce your glaucoma medication.
Location: United States, California, San Clemente
Employees: 501-1000
Phone: +1 949-367-9600
Total raised: $59.5M
Founded date: 1998
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.02.2013 | - | $30M | - |
| 03.02.2011 | - | $29.5M | - |
Mentions in press and media 16
| Date | Title | Description |
| 25.06.2025 | NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record | NEW YORK, June 25, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Sch... |
| 20.02.2025 | The Rise of Healthcare Marketing: A New Era of Innovation and Strategy | The healthcare marketing landscape is evolving. Agencies are no longer just service providers; they are strategic partners in the healthcare ecosystem. Two recent developments highlight this shift: Moon Rabbit's impressive growth and Strate... |
| 19.02.2025 | Moon Rabbit Wraps 2024 with Key Executive Hires, New NYC Headquarters, Major Client Wins | Healthcare agency also won Fierce Pharma's 'Best New Brand Launch' award, opened London office, instituted workplace enhancements for expanding team NEW YORK, Feb. 19, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and m... |
| 13.02.2025 | iVeena: $3 Million (Series B-2) Raised For Accelerating Development Of IVMED-85 For Myopia | iVeena Delivery Systems – a biopharmaceutical company advancing IVMED-85 to treat pediatric myopia – announced that it has closed its fully subscribed Series B-2 financing of $3 million. This funding will support iVeena’s pursuit of advanci... |
| 16.09.2024 | BostonSight Holds Annual FitAcademy Retreat for Cornea and Contact Lens Residents and Fellows | FitAcademy Class of 2024 We are incredibly grateful for our sponsors: NECO, Glaukos Corporation, Contamac, and Tangible Science. We have seen their continued support year after year.” — Karen G. Carrasquillo, OD, PhD, FAAO, FSLS, FBCLANEEDH... |
| 09.09.2024 | Managing Compliance Risk in Life Sciences: How Can IT and Quality Teams Root it Out | www.sware.com In this free webinar, learn how information technology (IT) and quality teams in life sciences organizations can both protect and deliver exceptional value by developing a systematic way to assess and grade risk, strengthening... |
| 07.05.2024 | Prevent Blindness to Host the 2024 ASPECT Patient Engagement and Advocacy Summit in Washington, D.C. | Prevent Blindness to host the 2024 ASPECT Patient Engagement and Advocacy Summit and Eyes on Capitol Hill event in Washington, D.C., May 14-16, 2024. Three-day event brings together patients, care partners, and public health champions to ad... |
| 27.12.2022 | Prevent Blindness Invites Patients and Caregivers to Join The Glaucoma Community as Part of January’s National Glaucoma Awareness Month | Prevent Blindness invites public to join "The Glaucoma Community" as part of January's National Glaucoma Awareness Month. “We invite patients, caregivers and professionals to join The Glaucoma Community today to get the support an... |
| 28.03.2016 | Glaukos gets the OK from Japan for its iStent device designed to treat glaucoma | Glaukos received pre-market approval for the iStent from the FDA back in 2012 – the first of its kind to do so in the United States, and according to the company’s website, this is actuall the smallest device to be approved by the FDA thus ... |
| 21.02.2013 | Medical Device Venture Capital Report for January 2013 | Medical device companies pulled in more than $255 million from investors in 29 deals during January, according to data provided to MassDevice.com by CB Insights Inc. The deals ranged widely in size, from a $25,000 seed round investment for ... |
Show more